drugset / Trial / NCT02188953

Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya

NCT02188953 ↗

RandomizedCrossoverQuadruple-blindPrevention

Summary

The purpose of this study is to pilot test the effectiveness, acceptability, and palatability of ACCS100 in a high-risk Kenyan population.

Timeline

Start
2014-08
Primary completion
2014-09
Completion
2014-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ACCS100 Other / unclassified 1 g Oral

Indications